Evosep and Mass Dynamics Build the AI-Ready Proteomics Ecosystem

SINGAPORE – September 29, 2026 – For the past two decades, mass spectrometry has been the undisputed heavyweight champion of protein identification. Yet, when it comes to late-stage pharmaceutical drug development and large-scale clinical trials, the technology has repeatedly lost ground to genomics and targeted affinity arrays. The culprit is rarely the mass spectrometer itself; rather, it is the chaotic, highly variable nature of physical sample preparation. Today, a new strategic collaboration announced at the Human Proteome Organization (HUPO) World Congress in Singapore aims to permanently close this gap.

Danish life science hardware developer Evosep has officially joined forces with collaborative bioinformatics platform Mass Dynamics. The partnership will bundle automated sample preparation hardware and chemistry with cloud-based analytical software, creating a standardized, end-to-end liquid chromatography-mass spectrometry (LC-MS) workflow. By marrying the physical and the digital, the alliance targets the pharmaceutical industry’s most persistent bottleneck: experimental reproducibility.

Solving the Reproducibility Crisis in Drug Discovery

Historically, multi-center pharmaceutical trials have treated proteomics with regulatory caution. Peer-reviewed variance studies reveal a stark reality: up to 75 percent of total technical variance in an LC-MS workflow stems from upstream extraction, tissue homogenization, and pre-analytical handling. In contrast, short-term instrument fluctuations account for a mere 10 to 16 percent.

When relying on manual pipetting and varying benchtop protocols, inter-laboratory quantitative coefficients of variation (CVs) frequently span 25 to 50 percent. For biopharma companies attempting to meet the strict FDA and ICH bioanalytical validation criteria—which typically stipulate precision within a 15 percent CV—this level of noise is fundamentally disqualifying.

The newly announced joint solution tackles this directly by eliminating human touchpoints. At the core of the physical workflow is the Evosep Lupo, a plug-and-play benchtop sample preparation instrument engineered exclusively for the company's proprietary Evokits. The system automates cell lysis, enzymatic digestion, and clean-up, loading purified peptides directly onto disposable trap-columns known as Evotips.

"Sample preparation remains one of the largest sources of variability in proteomics," commented Morten Bern, CEO of Evosep. "Through this collaboration, we can provide customers with a standardized solution that combines automated sample preparation with software-driven quality control, enabling reproducible proteomics at pharmaceutical scale."

By decoupling the sample loading and washing steps from the main analytical gradient, the hardware compresses intra-day CVs to below 10 percent, pushing the technology well within the regulatory thresholds required for clinical biomarker endpoints.

Preparing the Proteome for the Age of AI

While hardware automation solves the physical chemistry problem, the data architecture dimension of this partnership is arguably its most strategic asset. Machine learning foundation models applied to biology—such as predictive algorithms for drug efficacy and structural proteomics—require pristine, standardized training inputs.

If a dataset contains uncorrected technical variation, such as varying missed cleavage rates from non-standardized trypsin digestion, neural networks will inevitably interpret that hardware-level noise as biological signal. As one computational biology director at a leading biotechnology firm noted privately, "Garbage in leads to hallucinations out. We cannot train multi-million-dollar predictive models on batch effects."

This is where Mass Dynamics enters the equation. Under the terms of the agreement, the software developer’s quality control and system suitability monitoring platform, MD QC, will be provided with every Lupo and Evokit purchase. The software ingests raw mass spec files alongside batch metadata, evaluating critical metrics like digestion efficiency, data matrix completeness, and unsupervised PCA clustering of technical replicates.

Paula Burton, CEO of Mass Dynamics, emphasized the necessity of this digital infrastructure. "Standardizing the experiment is what makes everything downstream possible," Burton stated. "Pharmaceutical organizations also need biological interpretation to be reproducible, connected, traceable, and reusable. By connecting standardized sample preparation with a shared analytical environment, each experiment can build on the work that came before it - allowing proteomics knowledge to compound across teams, studies, and increasingly automated scientific workflows."

Furthermore, the software is built with an "agent-ready" architecture. Utilizing Model Context Protocol (MCP) endpoints and automated APIs, autonomous scientific agents can query datasets, evaluate QC metrics, and extract protein lists programmatically without requiring manual graphical interface interaction.

Hardware Meets SaaS: A New Commercial Paradigm

Beyond the laboratory bench, the alliance signals a broader shift in the commercial strategy of life science tools. Historically, the market has been dominated by vertically integrated instrument conglomerates that optimize end-to-end software exclusively for their proprietary hardware.

By tying automated consumable hardware to proprietary cloud quality-control software, these two niche toolmakers are building an integrated ecosystem capable of competing with those walled gardens. The business model is potent: consumable pull-through generated by the automated prep kits creates recurring revenue, while the digital SaaS layer creates high customer retention and workflow stickiness.

With a target unit economic cost of approximately ten dollars per sample, the integrated platform lowers the financial barrier for routine clinical and discovery proteomics. This aggressive pricing strategy enables biopharma companies to generate massive, 10,000-plus patient datasets affordably, further embedding the joint workflow into the core operations of pharmaceutical research and development.

Competing Against the Conglomerate Walled Gardens

The timing of this partnership is particularly notable when viewed alongside broader industry movements. Just one day prior to this announcement, Thermo Fisher Scientific entered into an official reseller agreement for the Evosep Eno high-throughput separation platform.

This creates a fascinating commercial paradox. On one hand, conglomerate giants are validating the Danish company’s front-end separation dominance by acting as distribution channels. On the other hand, by partnering with Mass Dynamics, the hardware maker is actively building an independent software moat that prevents it from becoming fully commoditized or absorbed by its massive distribution partners.

The joint solution operates as an open, vendor-neutral layer. An enterprise pharmaceutical laboratory running different fleets of mass spectrometers—perhaps Orbitrap Astrals in one facility and timsTOF systems in another—can now standardize their sample preparation and quality reporting across all sites, regardless of the downstream instrument vendor.

In the race to map the proteome and accelerate drug discovery, the winners will not necessarily be the companies that build the most sensitive mass spectrometers. Instead, the high ground belongs to those who can guarantee that a biological sample processed in Boston yields the exact same digital knowledge when analyzed in Basel.